Clinical trial · Observational
Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related Cardiotoxicity
NCT02798679CI-TRIAL-00061499completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether pre-existing cardiac fibrosis is a predictor of cancer treatment-related cardiotoxicity.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cardiotoxicity | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Cardiotoxicity assessed clinically or by cardiac MRI
- timeFrame
- 24 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: * Stage I-III breast cancer or lymphoma with a \>2 year life expectancy * A treatment plan that includes anthracyclines and/or trastuzumab * Age \>45 years * Able to hold breath for 10 seconds * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 Exclusion Criteria: * Refusal or inability to provide informed consent * Known heart failure or LVEF \<50% * Heart rate over 100 bpm * Renal dysfunction with GFR \<30 mL/min/1.73m2 * Participants with pacemakers, defibrillators, functioning neurostimulator devices or other implanted electronic devices * Symptomatic claustrophobia * Plans to move within 24 months of enrollment
References
Publications (0)
Data not yet available
No reference posted for this study.